Investors
Press Releases
Press releases issued by Palatin are accessible below. These press releases contain additional information about our business, clinical trial developments, research and development activities, financial achievements, and strategic partnerships.
Found 348 Results
Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results
September 26, 2024
Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
September 9, 2024
FDA Confirms Acceptability of Palatin’s Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)
August 28, 2024
First Patient Dosed in Phase 2 Clinical Study of Palatin’s Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity
August 22, 2024
Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity
June 12, 2024
Page 5 of 35